Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 370
- Registration Number
- NCT06633783
- Locations
- 🇨🇳
Xuancheng People's Hospital, Xuancheng, Anhui, China
🇨🇳Huizhou Central People's Hospital, Huizhou, Guangdong, China
🇨🇳Luoyang Third People's Hospital, Luoyang, Henan, China
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 476
- Registration Number
- NCT05816057
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳NanFang Hospital, Guangzhou, Guangdong, China
🇨🇳CANGZHOU People's Hospital, Cangzhou, Hebei, China
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
- Conditions
- Neutropenia
- Interventions
- Drug: pegfilgrastim, 60mcg/kgDrug: pegfilgrastim,30mcg/kgDrug: pegfilgrastim, 100mcg/kgDrug: filgrastim, 5mcg/kg
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 200
- Registration Number
- NCT01918241
- Locations
- 🇨🇳
Cancer Institute and Hospital, CAMS, Beijing, China
Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 24
- Registration Number
- NCT01637493
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
- Conditions
- NauseaVomitingChemotherapy
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 144
- Registration Number
- NCT00503386
- Locations
- 🇨🇳
Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Hunan Provincial Tumor Hospital, Changsha, Hunan, China